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a b s t r a c t
Staphylococcus epidermidis is a major cause of nosocomial infections owing to its ability to form bioﬁlms
on the surface ofmedical devices. Bioﬁlms are surface-adhered bacterial communities. Inmature bioﬁlms
these communities are encased in an extracellular matrix composed of bacterial polysaccharides, pro-
teins and DNA. The antibiotic resistance of bacteria present in bioﬁlms can be up to 1000-fold higher
compared with the planktonic phenotype. Host defence peptides (HDPs) are considered to be excellent
candidates for the development of novel antibiotics. Recently, we demonstrated that a short variant
of the HDP chicken cathelicidin-2, peptide F2,5,12W, has potent antibacterial and lipopolysaccharide-
neutralising activities. This study reports on the antibioﬁlmactivity of peptide F2,5,12Wagainst two strains
of S. epidermidis, includingamultiresistant strain. Peptide F2,5,12Wpotently inhibited the formationof bac-
terial bioﬁlms in vitro at a low concentration of 2.5M, which is below the concentration required to kill
or inhibit growth (minimal inhibitory concentration=10M). Moreover, peptide F2,5,12W also impaired
existing S. epidermidis bioﬁlms. A 4-h challenge of pre-grown bioﬁlms with 40M F2,5,12W reduced the
metabolic activity of thewild-type strain bioﬁlm completely and reduced that of themultiresistant strain
bioﬁlmby>50%. It is concluded that F2,5,12Wprevents bioﬁlm formation and impairsmature S. epidermidis
bioﬁlms.
© 2011 Elsevier B.V. and the International Society of Chemotherapy. Open access under the Elsevier OA license.. Introduction
Staphylococcus epidermidis is a major cause of infections related
o indwellingmedical devices such as intravascular catheters, cere-
rospinal ﬂuid shunts, peritoneal dialysis catheters, intraocular
enses, cardiac pacemakers and prosthetic joints [1]. It is an impor-
antmember of the human skin andmucousmembranemicroﬂora
nd can easily be transmitted to the surfaces of these devices
hen they are implanted or manipulated. S. epidermidis adheres
o and grows on medical devices, which may lead to a mature
ioﬁlm consisting of cells embedded in a sticky extracellular slime
omposed of bacterial polysaccharides, proteins and DNA. This
atrix renders the S. epidermidis bioﬁlm resistant to antibiotics and
ost defence systems and makes it difﬁcult or almost impossible
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Open acceto eradicate. Bacteria in bioﬁlms can be up to 1000-fold more
resistant to antibiotic treatment than the planktonic phenotype
[2].
The rising number of infections caused by bacterial isolates
resistant to conventional antibiotics has led to an intense search
for novel antimicrobials and chemotherapeutics, including the
use of host defence peptides (HDPs). HDPs comprise a class
of antibiotic compounds, i.e. naturally occurring peptides, that
exhibit broad antibacterial and/or immunomodulatory properties
[3].
Recently, the chicken HDP cathelicidin-2 (CATH-2) has been
identiﬁed [4]. We demonstrated that CATH-2 displays potent
antibacterial activity against a variety of bacteria, includingbiowar-
fare agents, and is able to inhibit lipopolysaccharide (LPS)-induced
cytokine release by peripheral blood mononuclear cells [5]. Fur-
thermore, we found that the peptide C1-15, comprising the ﬁrst
15 N-terminal amino acids of CATH-2, is the core element of
CATH-2 required for antibacterial activity. The antibacterial and
ss under the Elsevier OA license.

















eig. 1. Biomass of a 24-h-old bioﬁlm of two different Staphylococcus epidermidis str
iomass by crystal violet (CV) staining and (B) metabolic activity determined by th
S.E.M.) of three experiments. * Signiﬁcantly different compared with BM185 (P<0.
PS-neutralising activities of C1-15 were subsequently improved
y tryptophan substitution of all three phenylalanine residues,
esulting in peptide F2,5,12W [6,7].
Here we report the inhibitory effect of F2,5,12W on S. epidermidis
ioﬁlm formation as well as on existing bioﬁlms.
. Materials and methods
.1. PeptideF2,5,12W (RWGRWLRKIRRWRPK) was purchased from Pepscan
herapeutics (Lelystad, The Netherlands). Purity was determined
sing high-performance liquid chromatography (HPLC) and was
90%.
ig. 2. Effect of F2,5,12W on Staphylococcus epidermidis bioﬁlm formation by (A and C) stra
late containing different concentrations of peptides. Culture without F2,5,12W was used
ollowing incubation at 35 ◦C for 24h, absorbance at 595nm (A595) was recorded to asse
taining (white bars) (A and B).Metabolic activity of the bioﬁlmwas determined by the ala
rror of the mean (S.E.M.) of at least three experiments. * Signiﬁcantly different comparedhe clinical isolate BM185 and the multiresistant strain BM492. (A) Quantiﬁcation of
arBlue® reduction assay. Values represent the mean± standard error of the mean
D630nm, optical density at 630nm.
2.2. Micro-organisms
The strains used were the S. epidermidis clinical isolate BM185
and the S. epidermidis multiresistant strain BM492.
2.3. Bacterial susceptibility assay
Antimicrobial susceptibility of S. epidermidis was determined
using the brothmicrodilutionmethod. Brieﬂy, two-fold serial dilu-
tions of F2,5,12W were prepared in Mueller–Hinton broth (MHB)
containing 0.5% glucose at a volume of 50L/well in 96-well ﬂat-
bottom tissue culture plates (Costar®; Corning Inc., Corning, NY).
Overnight cultures of S. epidermidis were diluted 1:50 in MHB con-
taining 0.5% glucose and 50L of this diluted culture was added
to each well and plates were incubated for 24h at 35 ◦C. The ﬁnal
concentration of F2,5,12W ranged between 0.6M and 40M. The
in BM185 and (B and D) strain BM492. Bacterial cells were inoculated in a 96-well
as a positive control, and media without culture was used as a negative control.
ss cell growth (line graph); bioﬁlm biomass was determined by crystal violet (CV)
marBlue® reduction assay (grey bars) (C andD). Data represent themean± standard
with controls without peptide (P<0.05). OD630/595, optical density at 630/595nm.































mig. 3. Effect of F2,5,12W on Staphylococcus epidermidis pre-formed bioﬁlm of (A and
late and were incubated for 24h to develop a mature bioﬁlm. Bioﬁlms were rins
h of incubation at 35 ◦C, bioﬁlm biomass was determined by crystal violet (CV) sta
eduction assay (grey bars) (C and D). OD630, optical density at 630nm.
inimal inhibitory concentration (MIC) was deﬁned as the lowest
eptide concentration that yielded no visible growth.
.4. Bioﬁlm formation and quantiﬁcation of activity against
ioﬁlms
Bioﬁlm formation was induced in 96-well ﬂat-bottom tissue
ulture plates (Costar®). First, overnight cultures of S. epidermidis
trains were diluted 1:100 in freshMHB containing 5% glucose and
100L aliquot of the diluted culture was added to each well.
ollowing incubation at 35 ◦C for 24h without shaking, each well
as washed twicewith phosphate-buffered saline (PBS) to remove
lanktonic bacteria.
The biomass of the bioﬁlm was quantiﬁed by semiquantitative
rystal violet (CV) staining. After removal of planktonic bacteria,
ellswere stainedwith 0.4% CV for 15min. Excess CVwas removed
y washing each well three times with PBS. Bound CV was solu-
ilised in100Lof 33%acetic acid and theoptical density at 630nm
as measured.
Metabolic activity of the bioﬁlm was determined with the
lamarBlue® assay (Invitrogen, Carlsbad, CA). Following removal
f planktonic bacteria, 100L of MHB containing 0,5% glucose and
% alamarBlue was added to each well. alamarBlue is a redox indi-
ator that both shows ﬂuorescence and changes colour in response
o chemical reduction. The extent of reduction is a reﬂection of bac-
erial viability [8]. Following 1h incubation at 37 ◦C, ﬂuorescence
as measured at excitation and emission wavelengths of 550nm
nd 590nm, respectively.
The effects of F2,5,12Won bioﬁlm formationwere determined byddition of different concentrations of peptide (0–40M) during
he 24-h bioﬁlm formation period. Cell growth was determined by
easuring the absorbance at 595nm.
Similarly, the effects of F2,5,12W onmature bioﬁlms were deter-
ined by incubating washed 24-h-old bioﬁlms with differentain BM185 and (B and D) strain BM492. Bacterial cells were inoculated in a 96-well
different concentrations of F2,5,12W were transferred onto the bioﬁlm. Following
(white bars) (A and B) and metabolic activity was determined by the alamarBlue®
concentrations of peptides (0–40M) for 4h. Positive controls
were untreated bioﬁlms with only MHB plus 0.5% glucose. All
experiments were performed in triplicate.
2.5. Statistical analysis
Differences between mean values of groups were evaluated
using one-way analysis of variance (ANOVA) and Dunnett’s post
hoc test and were considered signiﬁcant at P<0.05.
3. Results
3.1. Minimal inhibitory concentration
The concentration of F2,5,12W required to inhibit the growth of
planktonic bacteria (MIC) was 10M (data not shown). No differ-
ences in MIC values were found between the antibiotic-sensitive
strain and themultiresistant strain. Both the clinical isolate and the
multiresistant strain showed no visible growth at a concentration
of 10M.
3.2. Bioﬁlm formation of two Staphylococcus epidermidis strains
Both strains formed bioﬁlms in vitro. Culturing for 24h resulted
in a signiﬁcantly larger biomass and greater metabolic activity
for the multiresistant strain (BM492) compared with the clini-
cal wild-type strain (BM185). Furthermore, a strong correlation
was observed between biomass quantiﬁed by CV staining (Fig. 1A)
and bioﬁlm metabolic activity quantiﬁed by alamarBlue reduction
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.3. Peptide F2,5,12W impairs Staphylococcus epidermidis bioﬁlm
ormation
An in vitro assay was performed to investigate the effects of
2,5,12W on bioﬁlm formation of S. epidermidis. As shown in Fig. 2A
nd B, all tested concentrations of the peptide inhibited bioﬁlm for-
ation. No differences were found between the two strains tested.
he amount of bioﬁlm biomass as well as the metabolic activity of
he bioﬁlm was signiﬁcantly inhibited at 2.5M peptide, a con-
entration four times below the MIC. This inhibitory effect was
ncreased to control levels at 10M, a concentration equal to the
IC (Fig. 2).
.4. F2,5,12W impairs the metabolic activity of existing bioﬁlms
Mature bioﬁlms are known to be more resistant to eradication
ompared with inhibition of de novo bioﬁlm formation. Therefore,
he activity of peptide F2,5,12W against mature bioﬁlms was evalu-
ted. Fig. 3 shows the amount of biomass quantiﬁed by CV staining
s well as metabolic activity quantiﬁed by the alamarBlue assay in
reated and untreated bioﬁlms.
Metabolic activity of S. epidermidis strain BM185 was signif-
cantly suppressed at 5M peptide, a concentration two times
elow the MIC (Fig. 3C). Higher concentrations further suppressed
he metabolic activity; at 40M the metabolic activity was similar
o the negative control levels. The effect of F2,5,12W treatment on
he biomass of strain BM185 was also dose-dependent (Fig. 3A).
he CV staining method is less reproducible than the alamarBlue
ssay and therefore was only signiﬁcant at a concentration of
0M.
Mature bioﬁlms of the multiresistant strain of S. epidermidis
M492were less susceptible to F2,5,12W treatment. However, a sig-
iﬁcant suppression of metabolic activity of the bioﬁlm was found
ollowing treatment with 40M F2,5,12W (Fig. 3D).
. Discussion
The involvement of S. epidermidis in infections associated with
ndwelling medical devices as well as the rapid development of
ultiple antibiotic resistance have continued to receive signiﬁ-
ant attention [9]. These types of infections are mediated by the
ropensity of S. epidermidis to adhere to surfaces and formbioﬁlms.
n general, bacteria grown as a bioﬁlm are protected from host
efences and often exhibit reduced susceptibility to antibiotics,
ontributing to the persistence of the bioﬁlm [2].
F2,5,12W, a short peptide based on chicken CATH-2, has been
eported tohavebroad antibacterial activity [7], but so far its effects
n bacterial bioﬁlms have not been evaluated.
The primary aim of this study was to investigate the effects of
2,5,12Won S. epidermidis bioﬁlms using a simple screeningmethod
o quantify bioﬁlms in vitro. The viability of bioﬁlm cells was con-
idered as themost important aspect when evaluating the effect of
ntimicrobial agents. CV stains polysaccharides in the extracellu-
ar matrix but does not distinguish between living and dead cells.
herefore, a quantiﬁcationmodel based on reduction of alamarBlue
y metabolically active cells was also included.
First, the antibacterial activity of F2,5,12W against two S. epi-
ermidis strains, including amultiresistant strain, was determined.
he results demonstrated that F2,5,12W exhibits activity with aMIC
alue of 10M for both strains.
In addition, it was demonstrated that F2,5,12W suppressed
ioﬁlm formation of both strains at a concentration four times
elow the MIC. Inhibition by F2,5,12W of bioﬁlm formation may be
he result of the inhibition of bacterial growth. However, inhibition
[ntimicrobial Agents 37 (2011) 476–479 479
of bioﬁlm formation was observed at concentrations that did not
affect bacterial growth. Therefore, the inhibitory effect of F2,5,12W
on bioﬁlm formation likely reﬂects decreased initial adhesion of
bacteria to the surface and subsequent development of the bioﬁlm.
Mature bioﬁlms are known to bemore refractory to eradication
relative to inhibition of de novo bioﬁlm formation. Therefore, the
effect of peptide F2,5,12W on mature bioﬁlms was evaluated. Low
concentrations of F2,5,12W had a better antimicrobial effect on the
weak bioﬁlm-producing S. epidermidis strain BM185 than on the
strong bioﬁlm-forming strain BM492. Both the architecture of a
thinner bioﬁlm and the total number of bacteria in such a bioﬁlm
may explain this ﬁnding.
Severalothergroupshave investigated theeffectofnaturalHDPs
or synthetic analogues on different types of bioﬁlms [10–15]. It was
reported that various peptides could be used to prevent bioﬁlm
formation.However, only three groups reported that peptideswere
effective in killing bacteria in a 24-h-old bioﬁlm [12,14,15].
In summary, we have demonstrated that at low concentrations,
below those that kill or inhibit growth, F2,5,12W strongly prevents
bacterial bioﬁlm formation in vitro. Moreover, F2,5,12W also impairs
existing S. epidermidis bioﬁlms.
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